Cerus (CERS) Upgraded at ValuEngine

Cerus (NASDAQ:CERS) was upgraded by ValuEngine from a “strong sell” rating to a “sell” rating in a research report issued on Thursday.

A number of other research firms have also recently commented on CERS. Zacks Investment Research cut shares of Cerus from a “buy” rating to a “hold” rating in a report on Wednesday. BTIG Research reissued a “neutral” rating on shares of Cerus in a report on Friday, December 8th. BidaskClub cut shares of Cerus from a “sell” rating to a “strong sell” rating in a report on Friday, December 29th. Cowen set a $6.00 target price on shares of Cerus and gave the stock a “buy” rating in a report on Thursday, October 5th. Finally, Robert W. Baird reissued a “buy” rating and issued a $5.00 target price on shares of Cerus in a report on Friday, December 1st. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus price target of $6.17.

Cerus (CERS) traded up $0.13 on Thursday, reaching $3.72. 493,639 shares of the company traded hands, compared to its average volume of 583,966. Cerus has a 1-year low of $1.93 and a 1-year high of $4.70. The company has a debt-to-equity ratio of 0.80, a current ratio of 3.71 and a quick ratio of 3.11. The company has a market capitalization of $424.40, a PE ratio of -6.31 and a beta of 1.93.

Cerus (NASDAQ:CERS) last posted its quarterly earnings data on Thursday, November 2nd. The biotechnology company reported ($0.12) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.15) by $0.03. Cerus had a negative net margin of 159.35% and a negative return on equity of 142.18%. The business had revenue of $10.80 million during the quarter, compared to analysts’ expectations of $11.95 million. During the same quarter in the prior year, the business posted ($0.14) earnings per share. Cerus’s revenue was up 5.9% compared to the same quarter last year. sell-side analysts anticipate that Cerus will post -0.57 EPS for the current fiscal year.

Several institutional investors have recently added to or reduced their stakes in the company. The Manufacturers Life Insurance Company increased its position in Cerus by 5.6% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 87,994 shares of the biotechnology company’s stock valued at $221,000 after purchasing an additional 4,688 shares during the period. Goldman Sachs Group Inc. increased its position in Cerus by 8.0% during the 2nd quarter. Goldman Sachs Group Inc. now owns 106,495 shares of the biotechnology company’s stock valued at $267,000 after purchasing an additional 7,864 shares during the period. Voya Investment Management LLC increased its position in Cerus by 22.0% during the 2nd quarter. Voya Investment Management LLC now owns 58,633 shares of the biotechnology company’s stock valued at $147,000 after purchasing an additional 10,570 shares during the period. Stephens Inc. AR increased its position in Cerus by 1.4% during the 2nd quarter. Stephens Inc. AR now owns 963,702 shares of the biotechnology company’s stock valued at $2,419,000 after purchasing an additional 12,973 shares during the period. Finally, UBS Asset Management Americas Inc. increased its position in Cerus by 59.3% during the 2nd quarter. UBS Asset Management Americas Inc. now owns 48,377 shares of the biotechnology company’s stock valued at $121,000 after purchasing an additional 18,000 shares during the period. 56.44% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: This piece of content was posted by American Banking News and is owned by of American Banking News. If you are accessing this piece of content on another publication, it was illegally stolen and republished in violation of United States & international trademark & copyright law. The correct version of this piece of content can be viewed at https://www.americanbankingnews.com/2018/01/04/cerus-cers-upgraded-at-valuengine.html.

About Cerus

Cerus Corporation is a biomedical products company. The Company is engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Company operates through blood safety segment. The Company’s INTERCEPT Blood System is based on its technology for controlling biological replication, and is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Cerus (NASDAQ:CERS)

Receive News & Ratings for Cerus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply